VIS 624

Drug Profile

VIS 624

Alternative Names: VIS624

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Visterra
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 29 Jun 2017 Visterra plans to initiate proof of efficacy studies in 2019 (Visterra pipeline, June 2017)
  • 15 Jan 2017 Preclinical trials in Multiple myeloma in USA (Parenteral) (Visterra pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top